Enzo Biochem Is Ready for Phase I Trial of HIV Gene Therapy

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Enzo Biochem Is Ready for Phase I Trial of HIV Gene Therapy

Reuters Health Information Services (12/19/97)

Abstract: Enzo Therapeutics has reportedly filed an Investigational New Drug application with the Food and Drug Administration to begin phase I testing of its StealthVector gene delivery system against HIV infection. The gene therapy approach was introduced earlier this year in a paper published in the May issue of Journal of Virology and uses a multitargeting strategy that prevents viral replication in the nucleus and the cytoplasm. In a Reuters interview, Cornell University's Jeffrey Laurence noted that Enzo's approach will be beneficial initially for two populations: HIV-positive people who have developed class resistance to sequential antivirals, and those who cannot comply with the complex drug regimens.

971222
AD972336

Copyright © 1997 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.

Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.